Mirabegron has been classified as a β 3 -adrenoceptor agonist approved for overactive bladder syndrome. We investigated possible cardiac effects of mirabegron in the absence or presence of β-adrenoceptor subtype antagonists. In view of its phenylethanolamine structure, we investigated whether mirabegron has indirect sympathomimetic activity by using neuronal uptake blockers.
Introduction
Mirabegron has been classified as a β 3 -adrenoceptor agonist (Takasu et al., 2007;  Figure 1 ). It induces β 3 -adrenoceptormediated relaxation of detrusor smooth muscle and was approved as a 'first-in-class' medicine for the management of overactive bladder syndrome (Chapple et al., 2014) . In view of its ability to activate β 3 -adrenoceptors, we used it to determine the contribution of β 3 -adrenoceptors to the contractility of human atria.
In human isolated atrium, Skeberdis et al. (2008) proposed that activation of β 3 -adrenoceptors caused an increase in contractile force and increased L-type Ca 2+ current in right atrial myocytes. However, Christ et al. (2011) demonstrated that the inotropic effects of the agonists used by Skeberdis et al. (2008) on human atrial trabeculae were not mediated through β 3 -adrenoceptors. To further understand the cardiac effects of human atrial β 3 -adrenoceptors, we investigated mirabegron directly on human atrial myocardium. Firstly, we studied the effects of mirabegron in the absence and presence of β-adrenoceptor subtype antagonists. We utilized the PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX), a non-selective inhibitor of PDE, to potentiate putative contractile effects of mirabegron, by limiting the metabolism of cAMP, as rationalized by Skeberdis et al. (2008) for β 3 -adrenoceptors. Interestingly, mirabegron has a phenylethanolamine structure, lacking meta-and para-hydroxyl groups ( Figure 1) . Ephedrine is similarly a phenylethanolamine (Figure 1 ), which causes cardiostimulant effects by being taken up into sympathetic nerves and releasing noradrenaline (Waldeck and Widmark, 1985; Bönisch and Trendelenburg, 1988) . This prompted us to investigate whether mirabegron is an indirect sympathomimetic amine. We therefore investigated the effects of mirabegron in the absence or presence of the neuronal blockers desipramine or phenoxybenzamine.
Methods

Human tissues
Right atrial appendages were obtained from patients undergoing coronary artery bypass surgery, aortic valve surgery, a combination of both or myomectomy surgery at The Prince Charles Hospital, Chermside. Patients provided written informed consent prior to surgery. Prospective patients were invited to participate in the study by the authors (W.M. and P.M.) who explained ethical considerations and provided patient information and revocation documents. The study, process for obtaining written informed consent, patient information, consent and revocation documents were approved by the Metro North Hospital and Health Services Human Ethics Committee, approval reference HREC/12/ QPCH/275. Patient characteristics are outlined in Table 1 .
Contractility studies
After excision, human right atrial appendages were immediately placed in modified oxygenated ice-cold Krebs solution containing (mM): Na + 125, K + 5, Ca 2+ 2.25, Mg
2+
Figure 1
Chemical structures of mirabegron, ephedrine and noradrenaline, highlighting the absence (mirabegron, ephedrine) and presence (noradrenaline) of meta-and para-hydroxyl groups on the phenyl group. Ephedrine causes β-adrenoceptor-mediated cardiostimulant effects in the heart by uptake into sympathetic nerve terminals and release of noradrenaline. The presence of meta-and para-hydroxyl groups on noradrenaline is required for direct activation of β-adrenoceptors. glucose 10 at 37°C, as described (Gille et al., 1985; Molenaar et al., 2007) . The tissues were attached to Swema SG4-45 strain gauge transducers, electrically stimulated with square-wave pulses of 5 ms duration and just over threshold voltage and force recorded on Labchart 8 for Windows (ADInstruments, Bella Vista, Australia). After determination of a length-tension curve, the length of each atrial trabeculum was set to obtain 50% of the resting tension associated with maximum developed force.
Experimental protocols
Mirabegron was added to the tissue bath to obtain single concentrations of 0.1, 1 or 10 μM after tissues had been preincubated with or without the PDE inhibitor IBMX (10 μM), β 3 -adrenoceptor antagonist L-748,337 (100 nM; Candelore et al., 1999; Wuest et al., 2009) , β 1 -adrenoceptor antagonist CGP 20712A (300 nM; Kaumann, 1986; Buxton et al., 1987) , β 2 -adrenoceptor antagonist ICI 118,551 (50 nM; Lemoine et al., 1985; Buxton et al., 1987; Kaumann and Lemoine, 1987; Hall et al., 1990) , neuronal uptake inhibitors desipramine (1 μM; Iversen, 1965) or phenoxybenzamine (5 μM; Gille et al., 1985; Iversen, 1965) . Tissues were incubated for 20 min with IBMX and 60 min with L-748,337, CGP 20712A, ICI 118,551 or desipramine before addition of mirabegron. Tissues were incubated for 90 min with phenoxybenzamine, which was then washed from the tissue bath (Gille et al., 1985) before mirabegron (10 μM) was added. Experiments were concluded by the addition of (À)-isoprenaline (200 μM) to saturate β 1 -, β 2 -and β 3 -adrenoceptors (Hall et al., 1990; Gauthier et al., 1996) .
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Patients presenting for heart surgery (coronary artery bypass surgery, aortic valve surgery or combination of both surgeries, myomectomy surgery) provided the samples of atrial tissue used. Group size numbers are indicated as numbers of (trabeculae/patients).
Values of n shown refer to the number of patients (not replicates) for statistical analysis and n > 5 for statistical analysis. During the course of the study, two patients chronically treated with carvedilol were used, and the results presented as preliminary data. Trabeculae/patient numbers were not always the same because right atrial appendages are inconsistent in terms of size and numbers of trabeculae. If an experiment had four different conditions, as in the experiment shown in Figure 3 , the priority was to allocate one trabeculae for each condition. However, some right atrial appendages did not have four trabeculae, and therefore, it was not always possible to complete the four conditions from tissues obtained from one patient. If there were >4 trabeculae from a patient, as for the example shown in Figure 3 , a replicate was included. The availability of patients, numbers of trabeculae and other variables such as surgeon were completely out of the control of the researchers and therefore may be considered to contribute to randomization. The experimenter and analyst (W.M. and P.M.) were not blinded for practical reasons. The experimenter was required to carry out all parts of each experiment including dissection and preparation of trabeculae and addition of investigational drugs. Every experimental intervention was digitally recorded on the trace in real time. At the conclusion of the experiment, data were analysed by the same experimenter and maintained in one Excel file (W.M. and P.M.). Data were normalized to the reference agonist (À)-isoprenaline (200 μM) and expressed as percentage for increases in contractility (Hall et al., 1990) to overcome variability in the magnitude of contractility (absolute values) due to differences in the size and other characteristics of trabeculae. Data were normalized to basal contractility for decreases in contractility and expressed as a percentage and not the (À)-isoprenaline response since it was considered more meaningful to express cardiodepression against basal contractility. Increases or decreases of force caused by mirabegron and increases by (À)-isoprenaline were measured as absolute values in units of mN prior to normalization. Only the increases or decreases in force were analysed statistically and not baseline values. Absolute values of basal and maximal forces for trabeculae of each group are given. Reductions in force of contraction were measured at 30 min (or minimum contractile force before 30 min, e.g. Figure 3 ). When comparing groups, the level of probability (P) was set at 0.05. Data were compared by one-way ANOVA with post hoc Table 2 Effect of mirabegron (0.1, 1 and 10 μM) on force of contraction (mN) in human right atrium. Data correspond to Figure 2A . n is number of trabeculae
Mirabegron concentration (μM) Pre-mirabegron Post-mirabegron n 0.1 8.9 ± 2.3 8.7 ± 2.2 6 1 8.5 ± 0.7 10.3 ± 1.2* 7 10 8.4 ± 1.1 10.0 ± 1.1* 22
Values shown are means ± SEM. *P < 0.05, significantly different from pre-mirabegron; paired t-test.
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tests if P < 0.05. Non-paired t-tests were used in experiments with two groups. Statistical analysis was carried out with the computer program GraphPad Instat® Version 3.10.
Materials
Mirabegron was purchased from Sapphire Bioscience (Redfern, Australia); L-748,337 from Tocris (Bristol, UK); and IBMX, (À)-isoprenaline, desipramine, ICI 118,551 and CGP 20712A were from Sigma Aldrich (Castle Hill, Australia). Phenoxybenzamine was a gift from GlaxoSmithKline (Stevenage, UK). Mirabegron and desipramine solutions were made fresh each day. Mirabegron (0.1 M) stock was prepared in DMSO. The maximal quantity of DMSO added to the 50 mL tissue bath was 5 μL (1-10 000 dilution), which did not modify atrial contractions (data not shown).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results
Cardiostimulant effects of mirabegron
Mirabegron (1 and 10 μM) caused significant concentrationdependent increases in contractile force in human right atrium (1 μM, 7.6 ± 2.6 %, n = 7; 10 μM, 10.2 ± 1.5%, n = 22, Figure 2 ). At a lower concentration (0.1 μM), mirabegron did not affect contraction (n = 8).
Enhancement of cardiostimulant effects of mirabegron by IBMX IBMX (10 μM) caused a 32± 2% (n = 19, % (À)-isoprenaline effect) increase in contractile force. In the presence of IBMX, mirabegron (0.1-10 μM) caused a further increase in force (Figure 2 ). The magnitude of the increase in contractile force caused by mirabegron (10 μM) was greater in the presence of IBMX than in its absence (Figure 2 ).
Mirabegron effects in the presence of β 1 -, β 2 -and β 3 -adrenoceptor antagonists
The β 3 -adrenoceptor antagonist L-748,337 (100 nM) had little effect on the increase in contractile force caused by mirabegron (10 μM) (Figure 3 ). In contrast, mirabegron (10 μM) caused a marked reduction in contractile force in Reductions in contractile force are represented as a percentage of basal force (% Basal). *P < 0.05. significant increase in force of contraction. The absolute mean values for contractile force (as mN) before and after mirabegron are given in Table 2 . Responses to mirabegron in the presence of IBMX (0.1 μM, 6/5; 1 μM, 7/6; 10 μM, 15/13, as trabeculae/patients) showed that IBMX potentiated responses to mirabegron (10 μM). **P < 0.05, significant effect of IBMX.
the presence of the β 1 -adrenoceptor antagonist CGP 20712A (300 nM), which was not affected by concomitant presence of L-748,337 (Figure 3 ) or the β 2 -adrenoceptor antagonist ICI 118,551 (Figure 4 ). In the presence of CGP 20712A, mirabegron often caused 'contractile dysfunction' (Figures 3  and 4 ), which could be overcome either by increasing the stimulus voltage or by (À)-isoprenaline (Figures 3 and 4) . L-748,337 (100 nM) had no effect on 'contractile dysfunction' caused by mirabegron (10 μM) in the presence of CGP 20712A (Figure 3) . During the course of these studies, we obtained atrial tissues from two patients with coronary artery disease who were chronically treated with the β-blocker carvedilol until heart surgery. Two trabeculae were obtained from each patient, equilibrated with IBMX (10 μM) and then mirabegron (10 μM). Mirabegron did not cause an increase in contractile force but, in contrast, reduced force in each trabeculum (individual values À24, À14, À16, À 90% of basal force). As carvedilol persistently blocks both β 1 -and β 2 -adrenoceptors (Molenaar et al., 2006) , these data also suggest that β 1 -and β 2 -adrenoceptors are not responsible for the cardiodepressive effects of mirabegron.
Mirabegron decreases contractile force in the presence of desipramine or phenoxybenzamine
We considered further the mechanism through which mirabegron causes increases in contractile force through the β 1 -adrenoceptor. The absence of meta-and parahydroxyl groups on the phenyl ring of mirabegron (Figure 1 ) suggests that this compound would not be an effective agonist at β 1 -adrenoceptors. Rather, this β 3 -adrenoceptor agonist may at least in part cause increases in force through an indirect sympathomimetic effect, as previously observed in isolated heart preparations with other sympathomimetic amines that also lack meta-and para-hydroxyl groups (Pesce and Adler-Graschinsky, 1983; Waldeck and Widmark, 1985) . Therefore, we tested the effects of mirabegron (10 μM) in the presence of desipramine or phenoxybenzamine (after washout), compounds reported to inhibit noradrenaline uptake into sympathetic nerves (Iversen, 1965) . Mirabegron (10 μM) reduced contractile force and caused 'contractile dysfunction' in the presence of desipramine or after phenoxybenzamine (5 μM), followed by washout of unbound phenoxybenzamine ( Figure 5 ).
Figure 3
Critical requirement of β 1 -adrenoceptors for cardiostimulant effects of mirabegron in human right atrium. The β 3 -adrenoceptor antagonist L-748,337 did not affect the mirabegron-induced increase in contractile force. Representative recordings are shown of the effects of mirabegron (10 μM), with or without L748,337 (100 nM), CGP 20712A (300 nM) or CGP 20712A (300 nM) + L748,337 (100 nM), in trabeculae from a 67 year male patient with coronary artery disease. The right-hand panels show expanded timescale recordings of individual contractions before (a) and after (b) the addition of mirabegron in the presence of CGP 20712A. Bar graph shows summary of data; numbers in brackets are trabeculae/patients. P < 0.05, *significantly different as indicated; ns, not significant; one-way ANOVA, Please notice evidence for 'contractile dysfunction' shown after (b), consisting of sudden long-lasting interruptions of contraction, prolonged contractions compared with contractions before CGP 20712A at subpanel (a) (please compare the fast-speed right-side panels a and b), fade of contraction or arrhythmic contractions.
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Discussion
We investigated the effects of mirabegron on contractility in isolated human right atrium to further clarify the role of β 3 -adrenoceptors. It was reported that β 3 -adrenoceptors mediate increases in contractile force in human right atrium (Skeberdis et al., 2008) but not by Christ et al. (2011) . The availability of mirabegron, which causes β 3 -adrenoceptor meditated relaxation of human detrusor muscle, provided the opportunity to re-address the question whether β 3 -adrenoceptors modify contractility in human atrium. We found that mirabegron at concentrations of 1 and 10 μM caused small increases in contractile force in human right atrium. In the presence of the β 1 -adrenoceptor selective antagonist CGP 20712A, desipramine or phenoxybenzamine (after washout), mirabegron caused a large reduction in contractile force and 'contractile dysfunction'. Both cardiostimulant and cardiodepressant effects were not affected by the β 3 -adrenoceptor antagonist L-748,337 (100 nM), a concentration estimated to occupy 83% of β 3 -adrenoceptors in human detrusor muscle (Wuest et al., 2009) . Taken together, these findings are compatible with with a lack of functional β 3 -adrenoceptors affecting contractile force in human atrium, in agreement with Christ et al. (2011) , but suggest that mirabegron may increase contractile force through release of noradrenaline.
Cardiostimulant effect of mirabegron
A potency (pEC 50 ) of mirabegron for relaxation of humanisolated detrusor muscle of 6.1 (Takasu et al., 2007) and 6.2 (Svalǿ et al., 2013) has been reported. To determine whether mirabegron has direct effects on human heart, we therefore exposed isolated human right atrium to concentrations of 0.1, 1 and 10 μM. Concentration-dependent increases in atrial contractile force were observed at 1 and 10 μM. The positive inotropic effects at 10 μM were, however, unaffected by the β 3 -adrenoceptor antagonist L-748,337 100 nM. The results of this study, which was carried out at 37°C, are consistent with the study of Christ et al. (2011) , who also did not observe β 3 -adrenoceptor-mediated increases in human atrial contractile force at both 37 and 24°C.
The increase in contractile force of mirabegron 10 μM was completely prevented by the β 1 -adrenoceptor antagonist CGP 20712A. The concentration of CGP 20712A used in the present study, 300 nM, occupies 99.7% β 1 -adrenoceptors (Kaumann, 1986; Buxton et al., 1987; Kaumann and Lemoine, 1987) , 9% β 2 -adrenoceptors (Buxton et al., 1987; Kaumann and Lemoine, 1987) but only 0.015% β 3 -adrenoceptors (Baker, 2010) . These data indicate a cardiostimulant mechanism mediated through β 1 -adrenoceptors but not β 3 -adrenoceptors. Increases in contractile force were enhanced by the non-selective PDE inhibitor IBMX, consistent with a β 1 -adrenoceptor-Gα s -protein-cAMP mechanism.
Cardiodepressant effects of mirabegron
Mirabegron caused a reduction in contractile force in the presence of the β 1 -adrenoceptor antagonist CGP 20712A. Furthermore, the initial voltage applied across the electrodes to maintain contractility often became insufficient to maintain normal contractions (compare Figure 3A, B) , possibly due to conduction block. An increase in voltage or the addition of (À)-isoprenaline overcame 'contractile dysfunction' and increased force (Figures 3 and 4) . The reduction in contractile force in the presence of CGP 20712A was not prevented by the β 3 -adrenoceptor antagonist L-748,337 or β 2 -adrenoceptor antagonist ICI 118,551 and is therefore not likely to be due to a β 3 -or β 2 -adrenoceptor mechanism.
Mirabegron (in the presence of IBMX) also caused a reduction in contractile force in the right atrium of two patients with evidence of heart failure that were chronically treated with carvedilol, in preliminary studies. Previously, we showed that chronic carvedilol treatment of patients with non-terminal heart failure reduced the inotropic sensitivity of atrial trabeculae to noradrenaline at β 1 -adenoceptors and adrenaline at β 2 -adrenoceptors~6-fold and~90-fold, respectively, but the potency of 5HT at 5HT 4 receptors was not reduced (Molenaar et al., 2006) . It is likely that the persistent blockade of β-adrenoceptors in right atrial trabeculae from patients chronically treated with carvedilol (Molenaar et al., 2006) prevented the observation of cardiostimulant effects but not cardiodepressant effects of mirabegron.
The mechanism of contractile dysfunction revealed in the presence of β 1 -adrenoceptor antagonism, desipramine or phenoxybenzamine was not identified in this study. However, the observation that contractility was restored by increasing stimulus voltage or by administering a saturating concentration of isoprenaline (200 μM) provides a starting point for understanding cardiodepressant mechanisms. Excitation-contraction coupling is complex, depending on precisely coordinated ion fluxes across sarcolemmal and intracellular membranes. Over 120 ion channels were identified and measured in human right atrium, each of which contribute to the action potential and therefore to the intracellular, time-dependent, concentrations of Ca 2+ (Chandler et al., 2009) . Systolic contractile force is Ca 2+ -dependent and therefore changes to ion channel fluxes that cause decreased intracellular Ca 2+ concentrations reduce systolic contractile force.
Mirabegron may have membrane-stabilizing properties.
Membrane-stabilizing properties of β-adrenoceptor antagonists (and partial agonists) have been reported previously in human (Nayler et al., 1969) and animal cardiac tissues Nayler et al., 1969; Van Zwieten, 1969; Langslet, 1970; Fitzgerald and O'Donnell, 1971; Fitzgerald et al., 1972) . 'Membrane-stabilizing properties' are used to describe 'local anaesthetic' and 'quinidine-like' effects of drugs (Davis, 1970) . For example, propranolol, at concentrations as low as 0.3 μM [but higher than those required to block β-adrenoceptors (Nayler et al., 1969; Gille et al., 1985) ], caused negative inotropic responses in isolated human right atrial and ventricular preparations (Nayler et al., 1969) . Similarly, high (micromolar) concentrations of propranolol and other β-blockers caused cardiodepressant effects including negative inotropic effects (Nayler et al., 1969; van Zwieten, 1969; Langslet, 1970) and increased the stimulus threshold voltage for contraction (Langslet, 1970) in animal-isolated cardiac preparations, effects not dissimilar to that observed for mirabegron. Additionally, Langslet (1970) observed ECG changes characterized by increased PQ, QRS and QT intervals in rat isolated perfused hearts, indicating changes in action potential generation and propagation. Activation of β-adrenoceptors with isoprenaline increases I CaL in human right atrium (Christ et al., 2011) and was sufficient to overcome cardiodepression caused by mirabegron.
Figure 5
Possible dependance on neuronal uptake for cardiostimulant effects of mirabegron (Mir) in human right atrium. Reduction of contractile force of mirabegron by desipramine (DMI) or phenoxybenzamine (PBZ). Shown are recordings of the effects of mirabegron 10 μM in the absence or presence of DMI (1 μM) or phenoxybenzamine (5 μM; 90 min incubation followed by washout) in trabeculae from a 42 year old patient with aortic valve disease. Bar graphs show summary of data; numbers in brackets are trabeculae/patients. *P < 0.05, significantly different; ns, not significant as indicated; one-way ANOVA,
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Desipramine and phenoxybenzamine prevent the cardiostimulant effects of mirabegron
Mirabegron is a phenylethanolamine derivative (Figure 1) . A feature of its structure is the absence of meta-and para-hydroxyl groups. An informative comparison can be made with other compounds with known sympathomimetic pharmacology that lack these groups, such as amphetamine, tyramine, mephentermine, ephedrine and β-phenylethylamine. These compounds cause cardiostimulant effects in isolated cardiac tisssues, which are reduced or completely abolished in tissues taken from animals pretreated with reserpine (Pesce and Adler-Graschinsky, 1983; Waldeck and Widmark, 1985) , which depletes cardiac stores of noradrenaline (Häggendal and Lindqvist, 1963) . Furthermore, pretreatment of tissues with cocaine, a sympathetic neuronal uptake inhibitor (Bönisch and Trendelenburg, 1988) , reduces the potency of amphetamine and β-phenylethylamine (Pesce and Adler-Graschinsky, 1983 ). The action of compounds like ephedrine (Waldeck and Widmark, 1985) and amphetamine are mediated through release of noradrenaline. It was concluded that indirectly acting sympathomimetic amines are substrates of neuronal uptake and release vesicular noradrenaline (Bönisch and Trendelenburg, 1988) . To determine whether the cardiostimulant effect of mirabegron is possibly mediated through an indirect mechanism, we investigated the effects of mirabegron in the absence and presence of desipramine or phenoxybenzamine, which inhibit neuronal uptake (Iversen, 1965) . Mirabegron reduced contractile force in the presence of desipramine or phenoxybenzamine. Both desipramine and phenoxybenzamine have mixed pharmacological properties. Desipramine (1 μM) causes 92% inhibition of noradrenaline uptake into sympathetic nerve terminals (Iversen, 1965) and has affinity for α 1 -, α 2A -adrenoceptors and muscarinic receptors [α 2A -Ki 5.0 μM determined from radioligand binding experiments, Cottingham et al., 2011; IC 50 values from radioligand binding experiments (α 1 -adrenceptors 0.57 μM, α 2A -adrenoceptors 9.2 μM, muscarinic receptors 0.6 μM, Wong et al., 1982) ]. Phenoxybenzamine belongs to a class of drugs called β-haloalkylamines, which include dibenamine that cause irreversible blockade of receptors through alkylation through a highly reactive ethyleniminium intermediate (Khan and Furchgott, 1982) . They are able to block α-adrenoceptors, muscarinic, histamine and serotonin receptors for several hours after washout (Khan and Furchgott, 1982) but not β 1 -or β 2 -adrenoceptors (Gille et al., 1985) . Incubation and washout of human right atrium with phenoxybenzamine causes a~1.2 log increase in potency of (À)-noradrenaline (Gille et al., 1985) .
In view of the mixed pharmacology of desipramine and phenoxybenzamine, the prevention of cardiostimulant effects of mirabegron in their presence could be due to a number of mechanisms. It is possible that the cardiostimulant effect of mirabegron involves its uptake into sympathetic nerve terminals, which is no longer possible in the presence of desipramine or phenoxybenzamine-treated tissues ( Figure 6 ). However, both desipramine and phenoxybenzamine also block α-adrenoceptors, and therefore, we cannot rule out the possibility that mirabegron blocks prejunctional α-adrenoceptors so that they have reduced autoinhibitory capacity on the release of noradrenaline from sympathetic nerve terminals. Recent studies have also demonstrated that mirabegron is an antagonist at α 1A -and α 1D -adrenoceptors with an affinity of approximately 1 μM (Alexandre et al., 2016) , that is, concentrations close to its affinity at β 3 -adrenoceptors but at least 10-fold higher than its peak plasma concentrations after therapeutic dosing (Krauwinkel et al., 2012) .
A limitation of the current study is that direct measurements of noradrenaline outflow from sympathetic nerves in right atrium (Abadie et al., 1996) were not determined. These would provide additional and definitive evidence whether the cardiostimulant effect of mirabegron is mediated through release of noradrenaline from sympathetic nerve terminals.
In summary, we have, in this study, observed separate cardiostimulant and cardiodepressant effects of mirabegron in human isolated right atrium, unrelated to the activation of β 3 -adrenoceptors. Instead, mirabegron activated β 1 -adrenoceptors, possibly through release of noradrenaline. Our evidence supports previous research showing that β 3 - Figure 6 Proposed effects of mirabegron in human heart. In sympathetic nerve terminals, noradrenaline is stored in storage vesicles (Basal). Synaptic noradrenaline is a substrate for neuronal uptake in the neuron by the noradrenaline transporter (NET, neuronal uptake, Chen et al., 2004) . It is proposed that mirabegron is taken up into sympathetic nerve terminals by the NET transporter, causes release of noradrenaline from storage vesicles by exocytosis which in turn activates β 1 -adrenoceptors (β 1 ) on post-junctional membranes of the myocardial cell. Mirabegron causes cardiodepression by an unknown mechanism (see text for further discussion). Thus mirabegron simultaneously causes cardiostimulation by an indirect mechanism and cardiodepression. The cardiostimulant, but not the cardiodepressant, effects of mirabegron can be prevented by neuronal uptake blockers phenoxybenzamine (PBZ) or desipramine (DMI) or by blockade of β 1 -adrenoceptors.
adrenoceptors do not modulate contractility of human hearts. The development of other selective β 3 -adrenoceptor agonists, vibegron (Di Salvo et al., 2017) , ritobegron and solabegron (Michel and Korstanje, 2016) , motivated by the identity of the β 3 -adrenoceptor as a therapeutic target to manage overactive bladder syndrome, provides further opportunities to investigate human heart β 3 -adrenoceptor function. Our studies may be helpful for the design and testing of future β 3 -adrenoceptor agonists intended for clinical use.
